XBP1 and neoplasm: With the rationale of targeting XBP1 for selective cancer cell killing, we have previously shown that immunogenic heteroclitic XBP1 peptides can evoke antigen-specific CTL with anti-tumor activities against MM cells and various solid tumor cancers [18,24–26].